Researchers sequence genome of Tasmanian devil contagious cancer

NewsGuard 100/100 Score

Researchers have sequenced the genome of a contagious cancer that is threatening the Tasmanian devil, the world's largest carnivorous marsupial, with extinction. Cataloguing the mutations present in the cancer has led to clues about where the cancer came from and how it became contagious.

The research has revealed that the cancer, which is spread between animals by biting, first arose from the cells of a single female Tasmanian devil. This animal is nicknamed "The Immortal Devil" because although she died more than 15 years ago, her DNA is living on in the contagious cancer cell line that she spawned. The cancer causes the appearance of tumours on the face of affected devils which grow rapidly and cause death within months.

"The Tasmanian devil cancer is the only cancer that is threatening an entire species with extinction," says Dr Elizabeth Murchison, lead author from the Wellcome Trust Sanger Institute. "Sequencing the genome of this cancer has allowed us to catalogue the mutations that caused this cancer to arise and to persist in the Tasmanian devil population."

The team found evidence for genetic differences between tumours, indicating that the cancer has genetically diverged during its spread through the Tasmanian devil population. They searched for these genetic differences between the tumours of 69 different devils from distant locations in Tasmania, allowing them to build up a map of the cancer's spread through the devil population. This indicates that some cancer sub-types may be more virulent than others.

"We found that devil cancer's genome has about 20,000 mutations. This is fewer mutations than are found in some human cancers and indicates that cancers do not need to be extremely unstable in order to become contagious." says Dr David Bentley, senior co-author from Illumina Cambridge Ltd. "Tracing the evolutionary history and spread of this cancer helps us to understand not only what caused this disease but also to predict how it might behave in the future."

The spread of cancer between individuals is normally prevented by the immune system, which can normally detect foreign tissues as "non-self". The team found some intriguing clues as to how the devil cancer may outwit the immune system, including mutations in a set of genes involved in immunity. However, future studies will be required to elucidate how cancer escapes the immune destruction.

"This research is important because it allows us to understand the pattern of disease spread and this may help contain the epidemic. However, we also now need to use the genome sequence to understand more about how this cancer became transmissible. Cancers that transmit through populations are obviously incredibly rare, but we should use the Tasmanian devil example to understand the process to be prepared in the extremely unlikely event that such an epidemic ever occurs in humans. ," says Professor Mike Stratton, senior author and Director of the Wellcome Trust Sanger Institute.

The next stage of the research will be to map the genomes of thousands of devil tumours in order to understand the genetic diversity present in the cancer and to investigate the genetic interactions between the cancer and the Tasmanian devil population.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer